ImmunityBio gets $50 million in financing via NantCapital

By Mary-Katherine Stinson

Lexington, Ky., Dec. 12 – ImmunityBio, Inc. received $50 million in debt financing to provide working capital and support its business operations from investor NantCapital, LLC, according to a press release.

NantCapital is an entity affiliated with Dr. Patrick Soon-Shiong, ImmunityBio’s executive chairman and global chief scientific and medical officer.

This financing is part of broader financing transactions that includes an additional approximately $50 million of equity financing from a single institutional investor and the conversion of approximately $56.6 million of debt held by NantWorks LLC into ImmunityBio equity.

ImmunityBio is a San Diego, Calif.-based developer of cell and immunotherapy products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.